|1.||de Jong, Steven: 9 articles (06/2011 - 08/2003)|
|2.||Aggarwal, Bharat B: 8 articles (10/2014 - 08/2009)|
|3.||Hong, Jin Tae: 7 articles (03/2015 - 01/2012)|
|4.||Krammer, Peter H: 7 articles (07/2010 - 04/2004)|
|5.||Ashkenazi, Avi: 6 articles (05/2015 - 03/2002)|
|6.||Zhang, Baolin: 6 articles (03/2015 - 12/2008)|
|7.||Andera, Ladislav: 6 articles (07/2013 - 06/2005)|
|8.||de Vries, Elisabeth G E: 6 articles (06/2011 - 08/2003)|
|9.||Debatin, Klaus-Michael: 6 articles (07/2005 - 07/2003)|
|10.||Fulda, Simone: 5 articles (05/2015 - 07/2003)|
05/01/2012 - "Preclinical and clinical studies of our and other groups have demonstrated that targeting the extrinsic apoptotic pathway by various death receptors agonists is a safe and effective anti-cancer strategy, which thus may become a new cornerstone of cancer therapy. "
12/01/2010 - "Proapoptotic receptor agonists (PARAs) targeting death receptors (DRs) 4 and 5 hold promise for cancer therapy based on their selective ability to kill malignant versus healthy cells. "
10/01/2007 - "Certain classes of tumor cells respond favorably to TRAIL due to the presence of cell surface death receptors DR4 and DR5. "
09/01/2011 - "Indeed, a variety of preclinical studies and several phase I and II clinical trials show that activation of TRAIL death receptors effectively induces apoptosis in cancer cells in vivo without therapy-limiting toxicity on normal cells. "
12/01/2008 - "This review covers the current knowledge about these four death receptors, summarizes pre-clinical approaches engaging these death receptors in anti-cancer therapy and also gives an overview about their application in clinical trials conducted to date."
|2.||Neoplasm Metastasis (Metastasis)
06/01/2010 - "Death receptors expressed on tumor cells can prevent metastasis formation by inducing apoptosis, but they also can promote migration and invasion. "
06/01/2010 - "Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells."
06/01/2010 - "Oncogenic K-Ras and its effector Raf1 convert death receptors into invasion-inducing receptors by suppressing the ROCK/LIM kinase pathway, and this is essential for K-Ras/Raf1-driven metastasis formation."
07/01/2001 - "In this study, to explore the possibility that the mutations of death receptors are involved in the metastasis mechanism, we analyzed the death domains of Fas and tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 and -2 (TRAIL-R1 and -R2) genes for the detection of somatic mutations in 57 breast cancers with (n = 34) or without (n = 23) metastasis to the regional lymph nodes. "
08/15/2010 - "Specific PDGFR-beta silencing in EWS cells enhanced the effects of TRAIL, possibly through an increase in the expression of death receptors 4 and 5. The combination of imatinib mesylate and TRAIL significantly inhibited the growth of primary tumors and decreased the incidence of spontaneous EWS pulmonary metastasis compared with either drug alone. "
|3.||Liver Diseases (Liver Disease)
11/01/2007 - "Understanding the mechanism of liver injury caused by death receptors will enable therapeutic strategies to ameliorate human liver diseases."
11/01/2014 - "Death receptors of the TNFR superfamily regulate cell death and inflammation and are implicated in liver disease and cancer. "
11/01/2003 - "Hepatocyte apoptosis by death receptors, hepatic inflammation, and fibrosis are prominent features of liver diseases. "
06/01/2000 - "The activation of the death receptors, tumor necrosis factor-receptor-1 (TNF-R1) or CD95, is a hallmark of inflammatory or viral liver disease. "
02/01/2000 - "Therapies targeting the death receptors, initiator caspases and mitochondria show potential promise in various liver disease, whereas targeting inhibition of executioner caspases may rapidly or in delayed fashion switch from apoptotic to necrotic cell death."
|4.||Stomach Neoplasms (Stomach Cancer)
12/01/2010 - "The synergistic effect between these two drugs is associated with up-regulation of death receptors and down-regulation of cIAP-1.The combination of TRAIL and bortezomib might be an effective regimen for the treatment of advanced gastric cancer."
11/01/2012 - "Since TRAIL resistance is associated with lipid rafts, in which both death receptors and epidermal growth factor receptors (EGFR) are enriched, our aim is to identify how lipid raft-regulated receptor redistribution influences the sensitivity of TRAIL in gastric cancer cells. "
07/01/2011 - "Cisplatin enhances TRAIL-induced apoptosis in gastric cancer MGC803 cells through clustering death receptors into lipid rafts."
03/01/2005 - "We showed that 5 Gy of X irradiation significantly up-regulated the expression of death receptors Fas and DR5 on the plasma membrane in gastric cancer cell lines MKN45 and MKN28, lung cancer cell line A549, and prostate cancer cell line DU145, and that subsequent treatments with agonistic molecules for these death receptors, Fas antibody CH11 and TRAIL, increased the formation of active fragment p20 of caspase 3 followed by the induction of apoptosis. "
|5.||Ovarian Neoplasms (Ovarian Cancer)
10/21/2005 - "Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer. "
01/01/2012 - "Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway."
10/21/2005 - "These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells."
|2.||TNF-Related Apoptosis-Inducing Ligand
|3.||TNF-Related Apoptosis-Inducing Ligand Receptors
|4.||NF-kappa B (NF-kB)
|7.||Indicators and Reagents (Reagents)
|9.||Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)